Special Issue "Research, Advances, Challenges and Perspectives in the Development of Vaccines against Dengue, Zika and Chikungunya Viruses"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 31 December 2020.
Interests: Host-pathogen interaction, flavivirus, PAMPs, Innate immunity, antiviral response, live attenuated vaccines, antigen design and production, host-targeted antiviral
Interests: Virus-Host interaction, arboviroses, programmed cell death, cell antiviral response, red queen effect
Zika (ZIKV), Dengue (DENV), and Chikungunya (CHIKV) viruses are arthropod-borne emerging or re-emerging pathogens mainly transmitted to humans by Aedes mosquitoes. With global warming and the spread of their mosquito vectors, these viruses are responsible for worldwide frequent outbreaks and constitute major public health problems. Beyond the classic clinical manifestations with fever, pain, rash, each virus is respectively responsible for serious complications such as haemorrhagic fever for DENV, congenital malformations for ZIKV, neurological complications like Guillain-Barré syndrome for CHIKV and ZIKV and chronic polyarthralgia for Chikungunya. The common feature of these viral infections is that there is no curative or prophylactic treatment. Vaccination, a prevention strategy, is the reference approach to a better public health and to limit future epidemics. To establish vaccines, it is necessary to define the host-pathogen interaction mechanisms and especially the molecular determinants of virulence. Among the challenges, it is necessary to consider the existence of the ADE phenomenon, a possible co-circulation of two or more of these viruses in endemic areas and the high prevalence of Guillain-Barré syndromes during some of these viral infections. A candidate vaccine must therefore be able to avoid inducing this type of response in humans and must be able to be used by the most vulnerable populations in endemic areas such as newborns or pregnant women. The purpose of this Special Issue “Research, advances, challenges and perspectives in the development of vaccines against Dengue, Zika and Chikungunya viruses” is to present the latest research results that advance our knowledge on the progress conception of vaccine strategies against these arboviruses. It is open to the submission of manuscripts, reviews, research, short communications, hypothesis, perspectives and point of view, that describe research or idea that can improve our knowledge on this issue for vaccines.
Dr. Wildriss Viranaicken
Dr. Pascale Krejbich
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- congenital complication
- Guillain-Barre syndrome
- host-cell response
- virulence factors
- vaccine candidate